Eiger BioPharmaceuticals, Inc. (EIGR) Deferred Tax Assets, Valuation Allowance USD 2013 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Eiger BioPharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from 2013 to 2023.
  • Eiger BioPharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $117 M, a 21.2% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $117 M +$20.4 M +21.2% Dec 31, 2023 10-K 2024-04-08
Q4 2022 $96.4 M +$25.1 M +35.2% Dec 31, 2022 10-K 2024-04-08
Q4 2021 $71.3 M +$10.5 M +17.4% Dec 31, 2021 10-K 2023-03-17
Q4 2020 $60.7 M +$6.95 M +12.9% Dec 31, 2020 10-K 2022-03-10
Q4 2019 $53.8 M +$7.56 M +16.3% Dec 31, 2019 10-K 2021-03-09
Q4 2018 $46.2 M +$13.6 M +41.8% Dec 31, 2018 10-K 2020-03-13
Q4 2017 $32.6 M +$3.42 M +11.7% Dec 31, 2017 10-K 2019-03-14
Q4 2016 $29.2 M +$17.3 M +145% Dec 31, 2016 10-K 2018-03-09
Q4 2015 $11.9 M +$5.61 M +89.1% Dec 31, 2015 10-K 2017-03-23
Q4 2014 $6.3 M -$21.3 M -77.1% Dec 31, 2014 8-K/A 2016-06-17
Q4 2013 $27.6 M Dec 31, 2013 10-K 2015-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.